Obsidian Therapeutics, Inc. Common Stock (OBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Obsidian Therapeutics, Inc. Common Stock (OBX) has a cash flow conversion efficiency ratio of 0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.01 Million) by net assets ($-276.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OBX market cap for the company's overall valuation and market capitalisation.
Obsidian Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Obsidian Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Obsidian Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Obsidian Therapeutics, Inc. Common Stock (OBX) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
0.002x |
|
Dorian LPG Ltd
NYSE:LPG
|
0.044x |
|
Yutong Optical
SHE:300790
|
0.026x |
|
SeAH Bestee
KO:001430
|
0.026x |
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
0.011x |
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
-0.038x |
|
Mercantile Bank Corporation
NASDAQ:MBWM
|
0.020x |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. View Obsidian Therapeutics, Inc. Common Stock stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-266.04 Million | $-90.39 Million | 0.340x | -20.98% |
| 2024-12-31 | $-174.43 Million | $-75.00 Million | 0.430x | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more